**Supplementary Table 1:** Secondary and tertiary indications of PTSD patients included (n=162). Data are reported as frequency and percentage of the total cohort n (%).

|  |  |  |
| --- | --- | --- |
|  | Secondary Indication | Tertiary Indication |
|  | **Frequency n (%)** | **Frequency n (%)** |
| Agoraphobia | - | 1 (0.62) |
| Anxiety | 39 (24.07) | 5 (3.09) |
| Attention deficit hyperactivity disorder | 5 (3.09) | 2 (1.23) |
| Autistic spectrum disorder | 1 (0.62) | - |
| Chronic pain | 5 (3.09) | 2 (1.23) |
| Cluster headaches | 1 (0.62) | - |
| Depression | 6 (3.70) | 18 (11.11) |
| Eating disorder | 2 (1.23) | 3 (1.85) |
| Ehlers-Danlos | 1 (0.62) | - |
| Fibromyalgia | 2 (1.23) | 1 (0.62) |
| Insomnia | 4 (2.47) | 10 (6.17) |
| Migraine | 1 (0.62) | - |
| Neuropathic pain | 1 (0.62) | - |
| OCD | 3 (1.85) | - |
| Total | **71 (43.83)** | **42 (25.93)** |

**Supplementary Table 2:** Cannabis status subgroup analysis of changes in IES-R from baseline to follow-up at 1-, 3- and 6-months. Reported as median (IQR) \*p<0.050, \*\*p<0.010, \*\*\*p<0.001

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **PROM** | **Follow-up month** | **n** | **Baseline Score median (IQR)** | **Follow-up Score median (IQR)** | **p-value** | **T-test statistic** | **Z-score** | **Effect size (r)** |
| Current User | | | | | | | | |
| **IES-R**  **Avoidance** | 1-month | 98 | 18.00 (14.00-23.00) | 16.00 (11.00-20.00) | <0.001\*\*\* | 3186.00 | -3.84 | -0.27 |
| 3-months | 71 | 18.00 (14.00-21.00) | 11.00 (6.00-17.00) | <0.001\*\*\* | 2049.50 | -5.04 | -0.42 |
| 6-months | 35 | 18.00 (14.00-21.00) | 12.00 (8.00-16.00) | <0.001\*\*\* | 398.00 | -3.41 | -0.41 |
| **IES-R**  **Intrusions** | 1-month | 98 | 23.00 (17.75-27.00) | 15.50 (9.75-21.25) | <0.001\*\*\* | 3634.50 | -6.11 | -0.44 |
| 3-months | 71 | 22.00 (17.00-27.00) | 12.00 (6.00-20.00) | <0.001\*\*\* | 2220.00 | -6.06 | -0.51 |
| 6-months | 35 | 19.00 (12.00-24.00) | 10.00 (5.00-16.00) | <0.001\*\*\* | 552.00 | -4.35 | -0.52 |
| **IES-R**  **Hyperarousal** | 1-month | 98 | 19.00 (13.75-21.00) | 12.50 (8.00-17.00) | <0.001\*\*\* | 3886.00 | -6.24 | -0.45 |
| 3-months | 71 | 18.00 (12.00-20.00) | 10.00 (6.00-15.00) | <0.001\*\*\* | 2150.00 | -5.98 | -0.50 |
| 6-months | 35 | 16.00 (10.00-20.00) | 8.00 (5.00-13.00) | <0.001\*\*\* | 529.00 | -3.97 | -0.47 |
| **IES-R**  **Total Score** | 1-month | 98 | 59.00 (49.00-68.00) | 44.00 (30.00-56.25) | <0.001\*\*\* | 4026.00 | -5.94 | -0.42 |
| 3-months | 71 | 57.00 (42.00-65.00) | 31.00 (18.00-50.00) | <0.001\*\*\* | 2273.00 | -6.03 | -0.51 |
| 6-months | 35 | 56.00 (37.00-62.00) | 28.00 (21.00-43.00) | <0.001\*\*\* | 576.50 | -4.29 | -0.51 |
| Ex-user | | | | | | | | |
| **IES-R**  **Avoidance** | 1-month | 16 | 20.00 (18.25-23.50) | 11.50 (8.25-21.50) | 0.012\* | 104.00 | -2.51 | -0.44 |
| 3-months | 12 | 20.50 (19.00-25.75) | 10.50 (4.75-21.25) | 0.008\*\* | 45.00 | -2.67 | -0.54 |
| 6-months | 5 | 20.00 (10.00-24.50) | 8.00 (6.00-18.00) | 0.042\* | 15.00 | -2.03 | -0.64 |
| **IES-R**  **Intrusions** | 1-month | 16 | 23.00 (19.50-24.75) | 15.00 (10.25-19.75) | 0.006\*\* | 121.00 | -2.75 | -0.49 |
| 3-months | 12 | 23.00 (18.75-23.75) | 11.50 (6.00-18.75) | 0.016\* | 51.00 | -2.40 | -0.49 |
| 6-months | 5 | 23.00 (11.50-23.50) | 11.00 (5.00-20.00) | <0.001\*\*\* | 8.00 | -1.10 | -0.35 |
| **IES-R**  **Hyperarousal** | 1-month | 16 | 18.00 (14.00-19.00) | 11.00 (5.50-15.00) | 0.006\*\* | 108.50 | -2.76 | -0.49 |
| 3-months | 12 | 17.50 (14.00-19.00) | 8.50 (3.00-11.75) | 0.005\*\* | 55.00 | -2.81 | -0.57 |
| 6-months | 5 | 14.00 (6.50-18.50) | 6.00 (3.50-13.00) | 0.109 | 6.00 | -1.60 | -0.51 |
| **IES-R**  **Total Score** | 1-month | 16 | 59.50 (51.25-68.00) | 38.00 (23.00-58.25) | 0.005\*\* | 122.50 | -2.82 | -0.50 |
| 3-months | 12 | 59.50 (51.25-68.00) | 31.00 (12.75-52.50) | 0.005\*\* | 55.00 | -2.81 | -0.57 |
| 6-months | 5 | 58.00 (28.00-66.00) | 28.00 (14.50-49.50) | 0.104 | 13.50 | -1.63 | -0.51 |
| Never Used | | | | | | | | |
| **IES-R**  **Avoidance** | 1-month | 13 | 20.00 (10.00-23.50) | 17.00 (10.50-21.00) | 0.082 | 52.50 | -1.74 | -0.34 |
| 3-months | 5 | 19.00 (10.00-23.00) | 18.00 (11.50-21.00) | 0.893 | 8.00 | -0.14 | -0.04 |
| 6-months | 5 | 19.00 (10.00-23.00) | 17.00 (10.00-21.00) | 0.715 | 6.00 | -0.37 | -0.12 |
| **IES-R**  **Intrusions** | 1-month | 13 | 23.00 (13.50-26.00) | 14.00 (9.50-27.00) | 0.289 | 52.50 | -1.06 | -0.21 |
| 3-months | 5 | 17.00 (8.50-25.50) | 18.00 (2.00-24.50) | 0.686 | 6.00 | -0.41 | -0.13 |
| 6-months | 5 | 17.00 (8.50-25.50) | 19.00 (7.50-24.50) | 0.686 | 9.00 | -0.41 | -0.13 |
| **IES-R**  **Hyperarousal** | 1-month | 13 | 17.00 (9.50-21.00) | 14.00 (7.00-20.00) | 0.059 | 63.00 | -1.89 | -0.37 |
| 3-months | 5 | 17.00 (5.50-19.00) | 9.00 (7.50-17.50) | 0.786 | 6.50 | -0.27 | -0.09 |
| 6-months | 5 | 17.00 (5.50-19.00) | 13.00 (6.50-19.50) | 0.683 | 6.00 | -0.41 | -0.13 |
| **IES-R**  **Total Score** | 1-month | 13 | 59.00 (33.50-70.50) | 49.00 (27.50-66.50) | 0.124 | 67.50 | -1.54 | -0.30 |
| 3-months | 5 | 54.00 (24.00-67.00) | 44.00 (32.50-62.00) | 0.893 | 7.00 | -0.14 | -0.04 |
| 6-months | 5 | 54.00 (24.00-67.00) | 52.00 (27.00-60.50) | 0.686 | 9.00 | -0.41 | -0.13 |

**Supplementary Table 3:** Subgroup analysis comparing the mean changes in PROMS from baseline to follow-up at 1-, 3- and 6-months between males and females. Reported as mean (±SD) \*p<0.050, \*\*p<0.010, \*\*\*p<0.001

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | **Males** | | **Females** | |  |
| **PROM** | **Follow-up month** | **n** | **Mean change from baseline** | **n** | **Mean change from baseline** | **P value** |
| **IES-R**  **Avoidance** | 1-month | 73 | -3.34±6.55 | 54 | -2.67±6.94 | 0.576 |
| 3-months | 54 | -5.35±8.46 | 34 | -6.41±7.35 | 0.549 |
| 6-months | 30 | -5.17±8.47 | 15 | -4.73±7.41 | 0.867 |
| **IES-R**  **Intrusions** | 1-month | 73 | -5.85±7.53 | 54 | -5.11±7.65 | 0.588 |
| 3-months | 54 | -6.78±8.80 | 34 | -8.68±8.10 | 0.312 |
| 6-months | 30 | -6.3±9.00 | 15 | -8.60±6.56 | 0.385 |
| **IES-R**  **Hyperarousal** | 1-month | 73 | -4.58±5.97 | 54 | -4.33±5.99 | 0.822 |
| 3-months | 54 | -6.00±6.87 | 34 | -5.88±6.60 | 0.937 |
| 6-months | 30 | -5.27±6.46 | 15 | -3.33±6.18 | 0.343 |
| **IES-R**  **Total Score** | 1-month | 73 | -13.77±18.34 | 54 | -12.11±18.49 | 0.617 |
| 3-months | 54 | -18.13±22.76 | 34 | -20.97±20.35 | 0.554 |
| 6-months | 30 | -16.73±22.26 | 15 | -16.67±17.47 | 0.992 |
| **EQ-5D-5L**  **Mobility** | 1-month | 76 | 0.00±0.82 | 57 | -0.19±0.85 | 0.188 |
| 3-months | 57 | -0.23±0.68 | 37 | -0.22±0.92 | 0.943 |
| 6-months | 33 | -0.09±0.58 | 18 | -0.22±0.81 | 0.505 |
| **EQ-5D-5L**  **Usual Activities** | 1-month | 77 | -0.53±1.06 | 56 | -0.46±0.97 | 0.705 |
| 3-months | 58 | -0.50±1.19 | 36 | -0.89±0.92 | 0.079 |
| 6-months | 33 | -0.45±1.03 | 17 | -0.35±1.27 | 0.762 |
| **EQ-5D-5L**  **Self Care** | 1-month | 77 | -0.13±0.73 | 56 | -0.13±0.74 | 0.970 |
| 3-months | 58 | -0.19±0.83 | 36 | -0.19±0.67 | 0.977 |
| 6-months | 33 | -0.06±0.61 | 17 | -0.18±0.60 | 0.754 |
| **EQ-5D-5L**  **Pain and Discomfort** | 1-month | 77 | -0.19±0.71 | 56 | -0.32±0.92 | 0.390 |
| 3-months | 58 | -0.28±0.83 | 36 | -0.53±0.94 | 0.179 |
| 6-months | 33 | -0.06±1.14 | 17 | 0.00±0.94 | 0.852 |
| **EQ-5D-5L**  **Anxiety and Depression** | 1-month | 77 | -0.71±1.28 | 56 | -0.70±1.04 | 0.932 |
| 3-months | 58 | -0.71±1.28 | 36 | -0.89±1.12 | 0.485 |
| 6-months | 33 | -0.48±1.39 | 17 | -0.76±1.20 | 0.485 |
| **EQ-5D-5L**  **Index Value** | 1-month | 77 | 0.14±0.22 | 56 | 0.13±0.22 | 0.775 |
| 3-months | 58 | 0.14±0.25 | 36 | 0.19±0.23 | 0.340 |
| 6-months | 33 | 0.08±0.27 | 17 | 0.14±0.23 | 0.374 |
| **GAD7** | 1-month | 77 | -5.22±5.96 | 56 | -4.61±5.28 | 0.540 |
| 3-months | 58 | -5.24±6.18 | 36 | -6.72±6.12 | 0.260 |
| 6-months | 33 | -4.61±6.73 | 17 | -5.24±7.23 | 0.761 |
| **SQS** | 1-month | 77 | 1.961±2.62 | 56 | 1.86±2.93 | 0.830 |
| 3-months | 58 | 2.12±2.66 | 36 | 0.89±2.87 | 0.037\* |
| 6-months | 33 | 1.33±3.028 | 17 | 0.12±2.78 | 0.174 |